These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2412053)

  • 21. Serotonin and the flow properties of blood.
    Walker RT; Matrai A; Bogar L; Dormandy JA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S35-7. PubMed ID: 2412054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
    Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
    Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
    Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
    Lichtenthal PR; Wade LD; Rossi EC
    Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function.
    Kirch W; Ohnhaus EE
    J Hypertens Suppl; 1986 Apr; 4(1):S67-71. PubMed ID: 2939216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S105-9. PubMed ID: 2412025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension.
    Egan B; Conlon ME; Campbell R; Schork N; Zwiefler A; Julius S
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):324S-330S. PubMed ID: 3415805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
    Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular pharmacology of ketanserin.
    Van Nueten JM; Vanhoutte PM
    Bibl Cardiol; 1984; (38):222-33. PubMed ID: 6099724
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of platelet-derived contractile agents on human digital arteries.
    Moulds RF; Iwanov V; Medcalf RL
    Clin Sci (Lond); 1984 Apr; 66(4):443-51. PubMed ID: 6697664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of increased lung serotonin levels to endotoxin-induced pulmonary hypertension in sheep. Effect of a serotonin antagonist.
    Demling RH; Wong C; Fox R; Hechtman H; Huval W
    Am Rev Respir Dis; 1985 Dec; 132(6):1257-61. PubMed ID: 2934013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet serotonin in essential hypertension and in mental depression.
    Baudouin-Legros M; Le Quan-Bui KH; Guicheney P; Kamal LA; Meyer P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S12-4. PubMed ID: 2412030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonergic mechanisms and blood pressure in sheep.
    Nelson MA; Coghlan JP; Denton DA; Mills EH; Scoggins BA; Spence CD; Whitworth JA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S117-9. PubMed ID: 2412029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical studies with ketanserin in hypertension.
    Waal-Manning HJ; Brown SA; Spears GF; Simpson FO
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S154-8. PubMed ID: 2412040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.